Differences in annual medication costs and rates of dosage increase between tumor necrosis factor-antagonist therapies for rheumatoid arthritis in a managed care population
- 30 April 2009
- journal article
- research article
- Published by Elsevier BV in Clinical Therapeutics
- Vol. 31 (4), 825-835
- https://doi.org/10.1016/j.clinthera.2009.04.002
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- Retrospective claims data analysis of dosage adjustment patterns of TNF antagonists among patients with rheumatoid arthritisCurrent Medical Research and Opinion, 2008
- Cost of care for patients with rheumatoid arthritis receiving TNF-antagonist therapy using claims dataCurrent Medical Research and Opinion, 2007
- Long term efficacy and safety of adalimumab plus methotrexate in patients with rheumatoid arthritis: ARMADA 4 year extended studyAnnals Of The Rheumatic Diseases, 2006
- Cost Effectiveness of Tumour Necrosis Factor-?? Inhibitors as First-Line Agents in Rheumatoid ArthritisPharmacoEconomics, 2006
- Pattern of infliximab utilization in rheumatoid arthritis patients at an academic medical centerArthritis Care & Research, 2005
- Methotrexate dosage reduction in patients with rheumatoid arthritis beginning therapy with infliximab: the Infliximab Rheumatoid Arthritis Methotrexate Tapering (iRAMT) trialCurrent Medical Research and Opinion, 2005
- Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: A randomized, controlled trialArthritis & Rheumatism, 2004
- Etanercept added to background methotrexate therapy in patients with rheumatoid arthritis: Continued observationsArthritis & Rheumatism, 2003
- Adalimumab, a fully human anti–tumor necrosis factor α monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: The ARMADA trialArthritis & Rheumatism, 2003
- A new method of classifying prognostic comorbidity in longitudinal studies: Development and validationJournal of Chronic Diseases, 1987